Carl Zeiss Meditec AG (LTS:0DHC) 5-Year EBITDA Growth Rate : 19.60% (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Carl Zeiss Meditec AG 5-Year EBITDA Growth Rate?

Carl Zeiss Meditec AG's EBITDA per Share for the three months ended in Dec. 2023 was €0.66.

During the past 12 months, Carl Zeiss Meditec AG's average EBITDA Per Share Growth Rate was -4.70% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 23.40% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 19.60% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 13.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Carl Zeiss Meditec AG was 24.40% per year. The lowest was -48.80% per year. And the median was 11.05% per year.

Competitive Comparison of Carl Zeiss Meditec AG's 5-Year EBITDA Growth Rate

For the Medical Instruments & Supplies subindustry, Carl Zeiss Meditec AG's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Carl Zeiss Meditec AG's 5-Year EBITDA Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Carl Zeiss Meditec AG's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Carl Zeiss Meditec AG's 5-Year EBITDA Growth Rate falls into.

Carl Zeiss Meditec AG 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Carl Zeiss Meditec AG (LTS:0DHC) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Carl Zeiss Meditec AG 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Carl Zeiss Meditec AG's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Carl Zeiss Meditec AG (LTS:0DHC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Carl Zeiss Meditec AG (LTS:0DHC) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

CZMWY:USA CZMWF:USA 1AFX:Italy AFXd:UK AFX:Germany AFX:Austria

Address

Goschwitzer Strasse 51-52, Jena, TH, DEU, 07745

Website

https://www.zeiss.com

Carl Zeiss Meditec is one of the largest medical technology companies in the world and it operates in two segments: Ophthalmic devices and Microsurgery. OPT, which made up 75% of sales in 2022, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.

Carl Zeiss Meditec AG (LTS:0DHC) Headlines

No Headlines